Development of A4 antibody for detection of neuraminidase I223R/H275Y-associated antiviral multidrug-resistant influenza virus

Kyeonghye Guk, Hyeran Kim, Miyeon Lee, Yoon-Aa Choi, Seul Gee Hwang, Gaon Han, Hye-Nan Kim, Hongki Kim, Hwangseo Park, Dongeun Yong, Taejoon Kang (), Eun-Kyung Lim () and Juyeon Jung ()
Additional contact information
Kyeonghye Guk: Korea Research Institute of Bioscience & Biotechnology (KRIBB)
Hyeran Kim: Korea Research Institute of Bioscience & Biotechnology (KRIBB)
Miyeon Lee: Korea Advanced Institute of Science and Technology (KAIST)
Yoon-Aa Choi: BioNano Health Guard Research Center, KRIBB
Seul Gee Hwang: Korea Research Institute of Bioscience & Biotechnology (KRIBB)
Gaon Han: Korea Research Institute of Bioscience & Biotechnology (KRIBB)
Hye-Nan Kim: Korea Research Institute of Bioscience & Biotechnology (KRIBB)
Hongki Kim: Korea Research Institute of Bioscience & Biotechnology (KRIBB)
Hwangseo Park: Sejong University
Dongeun Yong: Yonsei University College of Medicine
Taejoon Kang: Korea Research Institute of Bioscience & Biotechnology (KRIBB)
Eun-Kyung Lim: Korea Research Institute of Bioscience & Biotechnology (KRIBB)
Juyeon Jung: Korea Research Institute of Bioscience & Biotechnology (KRIBB)

Nature Communications, 2020, vol. 11, issue 1, 1-11

Abstract: Abstract The emergence and spread of antiviral drug-resistant viruses have been a worldwide challenge and a great concern for patient care. We report A4 antibody specifically recognizing and binding to the mutant I223R/H275Y neuraminidase and prove the applicability of A4 antibody for direct detection of antiviral multidrug-resistant viruses in various sensing platforms, including naked-eye detection, surface-enhanced Raman scattering-based immunoassay, and lateral flow system. The development of the A4 antibody enables fast, simple, and reliable point-of-care assays of antiviral multidrug-resistant influenza viruses. In addition to current influenza virus infection testing methods that do not provide information on the antiviral drug-resistance of the virus, diagnostic tests for antiviral multidrug-resistant viruses will improve clinical judgment in the treatment of influenza virus infections, avoid the unnecessary prescription of ineffective drugs, and improve current therapies.

Date: 2020
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-020-17246-w Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-17246-w

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-020-17246-w

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().